canagliflozin
AssetSmall moleculeAlso Canagliflozin 300 mg, Canagliflozin + Metformin hydrochloride (Fixed Dose Combination), JNJ-28431754, TA-7284
Sodium-glucose cotransporter 2 (SGLT2) inhibitor that lowers blood glucose by increasing urinary glucose excretion.
- Stage
- Approved
- Modality
- Small molecule
- Target
- AMPK signalling
- Indications
- 21
- Trials
- 1,421
- Developers
- 2
Indications
21Albuminuria
Approvedaccessdata.fda.gov7 Oct 2026
Cardiovascular death
Approvedaccessdata.fda.gov7 Oct 2026
Cardiovascular disease
Approvedaccessdata.fda.gov7 Oct 2026
18 more
- Targets and what it contains8
- Owner and partners2
- Trials1,421
- Evidence for its targets8
- Competitors12
- Aging relevance3
- Signals15
Every asset’s record: target, stage, trials and the evidence behind it.
See ProUpdated 7 Oct 2026 · 32 sources